Omega Therapeutics, Inc. Common Stock
OMGA
OMGA was delisted on the 24th of February, 2025.
70 hedge funds and large institutions have $187M invested in Omega Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 11 closing their positions.
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
23% more capital invested
Capital invested by funds: $152M → $187M (+$35.1M)
11% more funds holding
Funds holding: 63 → 70 (+7)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
34% less call options, than puts
Call options by funds: $188K | Put options by funds: $287K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.86M |
| 2 |
Millennium Management
New York
|
+$1.15M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$552K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$228K |
| 5 |
BlackRock
New York
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$922K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$879K |
| 3 |
Squarepoint
New York
|
-$417K |
| 4 |
Morgan Stanley
New York
|
-$204K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$143K |
OMGA Hedge Fund Activity: Q1 2024 in Review
70 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q1 2024, worth a combined $187M — up 23% from $152M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new OMGA positions and 11 closed out — a net gain of 8 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.86M. The largest seller was Zacks Investment Management, exiting entirely with an estimated $922K sold.
- 70 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q1 2024, up from 63 in Q4 2023.
- Funds reported $187M of Omega Therapeutics, Inc. Common Stock stock for Q1 2024, up 23% quarter-over-quarter.
- 19 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q1 2024 and 11 closed out, a net change of +8 holders.
- The largest Omega Therapeutics, Inc. Common Stock buyer in Q1 2024 was Fidelity Investments, an estimated $3.86M added.
- The largest Omega Therapeutics, Inc. Common Stock seller in Q1 2024 was Zacks Investment Management, an estimated $922K sold.
Based on aggregated 13F filings for Q1 2024.